Dirozalkib

Dirozalkib is a drug that was developed by Xuanzhu Biopharmaceutical for the treatment of non-small cell lung cancer. It is an anaplastic lymphoma kinase inhibitor.
It was approved for use in China in August of 2025.
Wikipedia contributors, "Dirozalkib", Wikipedia, revision 1383467275, retrieved 20 November 2026, source, CC BY-SA 4.0.